• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

磷酰二胺吗啉寡聚物的体外验证。

In Vitro Validation of Phosphorodiamidate Morpholino Oligomers.

机构信息

Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, WA 6150, Australia.

Perron Institute for Neurological and Translational Science, the University of Western Australia, Perth, WA 6009, Australia.

出版信息

Molecules. 2019 Aug 12;24(16):2922. doi: 10.3390/molecules24162922.

DOI:10.3390/molecules24162922
PMID:31408997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6719133/
Abstract

One of the crucial aspects of screening antisense oligonucleotides destined for therapeutic application is confidence that the antisense oligomer is delivered efficiently into cultured cells. Efficient delivery is particularly vital for antisense phosphorodiamidate morpholino oligomers, which have a neutral backbone, and are known to show poor gymnotic uptake. Here, we report several methods to deliver these oligomers into cultured cells. Although 4D-Nucleofector™ or Neon™ electroporation systems provide efficient delivery and use lower amounts of phosphorodiamidate morpholino oligomer, both systems are costly. We show that some readily available transfection reagents can be used to deliver phosphorodiamidate morpholino oligomers as efficiently as the electroporation systems. Among the transfection reagents tested, we recommend Lipofectamine 3000™ for delivering phosphorodiamidate morpholino oligomers into fibroblasts and Lipofectamine 3000™ or Lipofectamine 2000™ for myoblasts/myotubes. We also provide optimal programs for nucleofection into various cell lines using the P3 Primary Cell 4D-Nucleofector™ X Kit (Lonza), as well as antisense oligomers that redirect expression of ubiquitously expressed genes that may be used as positive treatments for human and murine cell transfections.

摘要

筛选用于治疗应用的反义寡核苷酸的关键方面之一是确信反义寡聚物能够有效地递送到培养的细胞中。对于具有中性骨架的反义磷酰胺吗啉寡聚物,有效的递送尤其重要,因为已知其具有较差的电穿孔摄取。在这里,我们报告了几种将这些寡聚物递送到培养细胞中的方法。虽然 4D-Nucleofector™或 Neon™电穿孔系统提供了有效的递送,并且使用较少的磷酰胺吗啉寡聚物,但这两个系统都很昂贵。我们表明,一些现成的转染试剂可用于有效地递送电穿孔磷酰胺吗啉寡聚物,与电穿孔系统一样有效。在测试的转染试剂中,我们推荐 Lipofectamine 3000™用于将磷酰胺吗啉寡聚物递送到成纤维细胞中,以及 Lipofectamine 3000™或 Lipofectamine 2000™用于肌母细胞/肌管。我们还提供了使用 P3 Primary Cell 4D-Nucleofector™ X Kit(Lonza)进行各种细胞系核转染的最佳方案,以及重定向表达普遍表达基因的反义寡聚物,这些基因可作为人类和鼠细胞转染的阳性治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f52d/6719133/3a27c4e6f26d/molecules-24-02922-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f52d/6719133/6afcbf31a363/molecules-24-02922-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f52d/6719133/3a27c4e6f26d/molecules-24-02922-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f52d/6719133/6afcbf31a363/molecules-24-02922-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f52d/6719133/3a27c4e6f26d/molecules-24-02922-g002.jpg

相似文献

1
In Vitro Validation of Phosphorodiamidate Morpholino Oligomers.磷酰二胺吗啉寡聚物的体外验证。
Molecules. 2019 Aug 12;24(16):2922. doi: 10.3390/molecules24162922.
2
In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.反义磷酰二胺吗啉代寡聚物(PMO)在营养不良犬和7号外显子缺失的杜氏肌营养不良症(DMD)患者中诱导的体外多外显子跳跃
Methods Mol Biol. 2018;1828:151-163. doi: 10.1007/978-1-4939-8651-4_9.
3
Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.在杜氏肌营养不良症的mdx52小鼠模型中使用磷酰二胺吗啉代寡聚物进行外显子跳跃疗法
Methods Mol Biol. 2018;1687:123-141. doi: 10.1007/978-1-4939-7374-3_9.
4
Triazine-cored polymeric vectors for antisense oligonucleotide delivery in vitro and in vivo.三嗪核聚合物载体用于体外和体内反义寡核苷酸递药。
J Nanobiotechnology. 2020 Feb 18;18(1):34. doi: 10.1186/s12951-020-0586-8.
5
Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.定量反义筛选和优化用于杜氏肌营养不良症外显子 51 跳跃。
Mol Ther. 2017 Nov 1;25(11):2561-2572. doi: 10.1016/j.ymthe.2017.07.014. Epub 2017 Jul 28.
6
In Vitro Delivery of PMOs in Myoblasts by Electroporation.电穿孔法在成肌细胞中递送 PMO。
Methods Mol Biol. 2022;2434:191-205. doi: 10.1007/978-1-0716-2010-6_12.
7
Exon Skipping Using Antisense Oligonucleotides for Laminin-Alpha2-Deficient Muscular Dystrophy.使用反义寡核苷酸进行外显子跳跃治疗层粘连蛋白α2缺乏型肌营养不良症
Methods Mol Biol. 2018;1828:553-564. doi: 10.1007/978-1-4939-8651-4_36.
8
Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers.反义磷酰二胺吗啉代寡聚物的细胞内递送策略
Antisense Nucleic Acid Drug Dev. 2000 Aug;10(4):263-74. doi: 10.1089/108729000421448.
9
Efficient exon skipping of SGCG mutations mediated by phosphorodiamidate morpholino oligomers.磷酸二酰胺吗啉寡聚物介导的 SGCG 突变的有效外显子跳跃。
JCI Insight. 2018 May 3;3(9):99357. doi: 10.1172/jci.insight.99357.
10
Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.气泡脂质体和超声照射可改善吗啉代寡聚物在营养不良性mdx小鼠骨骼肌中的局部递送。
Mol Pharm. 2014 Mar 3;11(3):1053-61. doi: 10.1021/mp4004755. Epub 2014 Jan 27.

引用本文的文献

1
Is Exon Skipping a Viable Therapeutic Approach for Vascular Ehlers-Danlos Syndrome with Mutations in Exon 10 or 15?外显子跳跃是否是 10 或 15 外显子突变的血管型 Ehlers-Danlos 综合征的可行治疗方法?
Int J Mol Sci. 2024 Aug 13;25(16):8816. doi: 10.3390/ijms25168816.
2
Direct Activation of Nucleobases with Small Molecules for the Conditional Control of Antisense Function.小分子直接激活核碱基用于反义功能的条件控制
Angew Chem Int Ed Engl. 2024 Apr 22;63(17):e202318773. doi: 10.1002/anie.202318773. Epub 2024 Mar 15.
3
Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.

本文引用的文献

1
Scavenger Receptor Class A1 Mediates Uptake of Morpholino Antisense Oligonucleotide into Dystrophic Skeletal Muscle.清道夫受体A1类介导吗啉代反义寡核苷酸进入营养不良性骨骼肌。
Mol Ther Nucleic Acids. 2019 Mar 1;14:520-535. doi: 10.1016/j.omtn.2019.01.008. Epub 2019 Jan 25.
2
Pre-mRNA Splicing Modulation by Antisense Oligonucleotides.反义寡核苷酸对前体mRNA剪接的调控
Methods Mol Biol. 2018;1828:415-437. doi: 10.1007/978-1-4939-8651-4_26.
3
Antisense Oligonucleotide-Mediated Terminal Intron Retention of the SMN2 Transcript.
剪接调节反义寡核苷酸作为遗传性代谢疾病的治疗方法。
BioDrugs. 2024 Mar;38(2):177-203. doi: 10.1007/s40259-024-00644-7. Epub 2024 Jan 22.
4
antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon.反义寡核苷酸介导的外显子跳跃效率与侧翼内含子的保留时间和外显子内的靶位位置相关。
RNA Biol. 2023 Jan;20(1):693-702. doi: 10.1080/15476286.2023.2254041.
5
Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology.用于神经系统的反义寡核苷酸疗法:从实验台到病床,重点关注小儿神经病学。
Pharmaceutics. 2022 Nov 5;14(11):2389. doi: 10.3390/pharmaceutics14112389.
6
Puerarin suppresses hypoxia-induced vascular endothelial growth factor upregulation in human retinal pigmented epithelial cells by blocking JAK2/STAT3 pathway.葛根素通过阻断 JAK2/STAT3 通路抑制缺氧诱导的人视网膜色素上皮细胞血管内皮生长因子上调。
Bioengineered. 2022 May;13(5):11636-11645. doi: 10.1080/21655979.2022.2070586.
7
In Vitro Delivery of PMOs in Myoblasts by Electroporation.电穿孔法在成肌细胞中递送 PMO。
Methods Mol Biol. 2022;2434:191-205. doi: 10.1007/978-1-0716-2010-6_12.
8
Ultrasound-targeted microbubble destruction mediated miR-492 inhibitor suppresses the tumorigenesis in non-small cell lung cancer.超声靶向微泡破坏介导的 miR-492 抑制剂抑制非小细胞肺癌的肿瘤发生。
Ann Med. 2021 Dec;53(1):2246-2255. doi: 10.1080/07853890.2021.2005254.
9
Targeted Exon Skipping: A Useful Control to Assess In Vitro and In Vivo Splice-Switching Studies.靶向外显子跳跃:评估体外和体内剪接转换研究的有用对照
Biomedicines. 2021 May 14;9(5):552. doi: 10.3390/biomedicines9050552.
10
Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in .非连续拼接事件改变反义介导的外显子跳跃结果。
Int J Mol Sci. 2020 Oct 18;21(20):7705. doi: 10.3390/ijms21207705.
反义寡核苷酸介导的SMN2转录本末端内含子保留
Mol Ther Nucleic Acids. 2018 Jun 1;11:91-102. doi: 10.1016/j.omtn.2018.01.011. Epub 2018 Jan 31.
4
Recent preclinical and clinical advances in oligonucleotide conjugates.寡核苷酸缀合物的最新临床前和临床进展。
Expert Opin Drug Deliv. 2018 Jun;15(6):629-640. doi: 10.1080/17425247.2018.1473375. Epub 2018 May 16.
5
Endoplasmic reticulum stress stimulates the release of extracellular vesicles carrying danger-associated molecular pattern (DAMP) molecules.内质网应激刺激携带危险相关分子模式(DAMP)分子的细胞外囊泡的释放。
Oncotarget. 2018 Jan 11;9(6):6707-6717. doi: 10.18632/oncotarget.24158. eCollection 2018 Jan 23.
6
Antisense oligonucleotides: the next frontier for treatment of neurological disorders.反义寡核苷酸:治疗神经紊乱的下一个前沿。
Nat Rev Neurol. 2018 Jan;14(1):9-21. doi: 10.1038/nrneurol.2017.148. Epub 2017 Dec 1.
7
FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides.美国食品药品监督管理局批准诺西那生用于治疗脊髓性肌萎缩症,使2016年成为剪接调节寡核苷酸之年。
Nucleic Acid Ther. 2017 Apr;27(2):67-69. doi: 10.1089/nat.2017.0665. Epub 2017 Feb 21.
8
Delivery is key: lessons learnt from developing splice-switching antisense therapies.递送是关键:从开发剪接转换反义疗法中汲取的经验教训。
EMBO Mol Med. 2017 May;9(5):545-557. doi: 10.15252/emmm.201607199.
9
Translational development of splice-modifying antisense oligomers.剪接修饰反义寡核苷酸的转化研究进展
Expert Opin Biol Ther. 2017 Jan;17(1):15-30. doi: 10.1080/14712598.2017.1250880. Epub 2016 Nov 2.
10
RNA therapeutics: RNAi and antisense mechanisms and clinical applications.RNA疗法:RNA干扰和反义机制及临床应用。
Postdoc J. 2016 Jul;4(7):35-50. doi: 10.14304/surya.jpr.v4n7.5.